유바이오로직스
Financials
Valuation Metrics
유바이오로직스's Market Cap is ₩3106B. At end of 2025 it was ₩4175B. Ranked #643 of 2,421 in KR market (top 27%), #266 of 1,640 on KOSDAQ (top 16%), #68 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 310.56B KRW | KR#643/2,421 Sec#68/231 |
| Revenue | 122.31B KRW | KR#1,302/2,421 Sec#82/231 |
| Net Income | 29.00B KRW | KR#575/2,421 Sec#34/231 |
| Total Assets | 240.23B KRW | KR#1,170/2,421 Sec#83/231 |
| Net Assets | 175.36B KRW | KR#1,032/2,421 Sec#71/231 |
| Employees | 353 | KR#686/2,421 Sec#60/231 |
| Value | ||
| P/E | 10.71x | KR#850/2,421 Sec#45/231 |
| P/B | 1.77x | KR#1,859/2,421 Sec#136/231 |
| P/S | 2.54x | KR#1,920/2,421 Sec#112/231 |
| EV/EBITDA | 6.63x | KR#355/2,421 Sec#11/231 |
| FCF Yield | 14.03% | KR#467/2,421 Sec#14/231 |
| Profitability | ||
| ROE | 16.54% | KR#253/2,421 Sec#14/231 |
| ROA | 12.07% | KR#186/2,421 Sec#17/231 |
| Op. Margin | 35.39% | KR#36/2,421 Sec#8/231 |
| Revenue Growth | -17.76% | KR#2,097/2,421 Sec#191/231 |
| Earnings Growth | -39.25% | KR#1,017/2,421 Sec#66/231 |
| Financial Health | ||
| Debt Ratio | 36.99% | KR#730/2,421 Sec#88/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | 43.57B KRW | KR#330/2,421 Sec#19/231 |
| Cash | 23.67B KRW | KR#1,145/2,421 Sec#78/231 |
| Current Ratio | 3.97x | KR#389/2,421 Sec#58/231 |
| Net Debt/EBITDA | -0.55x | KR#480/2,421 Sec#29/231 |
| Performance | ||
| 1Y Return | -38.86% | KR#1,806/2,421 Sec#149/231 |
| 1M Return | -1.52% | KR#1,420/2,421 Sec#108/231 |
| From 52W High | -52.26% | KR#1,499/2,421 Sec#116/231 |
| 1Y MDD | -54.38% | KR#1,182/2,421 Sec#99/231 |
| Trading | ||
| Volume | 50,690 shares | KR#1,121/2,421 Sec#110/231 |
| Trading Value | 427.3M KRW | KR#984/2,421 Sec#98/231 |
| Foreign Own. | 6.19% | KR#715/2,421 Sec#63/231 |
| Per Share | ||
| EPS | 789 KRW | KR#813/2,421 Sec#58/231 |
| BPS | 4,771 KRW | KR#1,531/2,421 Sec#109/231 |
Company Info
Established in 2010 and listed on KOSDAQ in 2017, this company is a specialized venture in vaccine manufacturing and biopharmaceutical contract research and manufacturing. It operates vaccine businesses, supplying 'Euvichol-S' to UNICEF and others, and provides biopharmaceutical CRMO services, with first and second factories and a research institute in Chuncheon. By expanding its cholera vaccine facilities, the company has established an annual production system of up to 90 million doses. It aims to become a global vaccine company through the development of diverse vaccine pipelines. Eubiologics is headquartered in Gangnam-gu, Seoul Special City.